

FOI/2027

30/11/23

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1. How many patients have been treated for advanced (FIGO Stages III and IV) ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months? If none, do you refer advanced ovarian cancer patients to another trust, and if so which one?

Q2. How many patients were treated in the past 3 months for ovarian cancer (any stage) with:

- Paclitaxel in combination with a platinum-based compound
- Platinum-based therapy alone (cisplatin or carboplatin)
- Bevacizumab in combination with paclitaxel and carboplatin
- Olaparib
- Olaparib + Bevacizumab
- Niraparib
- Rucaparib

Q3. If data for HRD (homologous recombination deficiency) testing is available, please provide how many HRD positive ovarian cancer patients were treated in the last 3 months with:

- Olaparib
- Olaparib + Bevacizumab
- Niraparib
- Other treatments

Q4. Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part.

Response:

The Southern Trust do not treat patients with ovarian cancer. These patients are referred to the Belfast Trust. If you wish to redirect your query to the Belfast Trust please contact them at the following email address: publicliaison@belfasttrust.hscni.net.

Email: Foi.Team@Southerntrust.hscni.net